Thyroid fine needle aspiration reporting rates and outcomes before and after Bethesda implementation: A single-center experience over 8 years

Ismail Alper TARIM, (Ondokuz Mayis University, Medical Faculty, General Surgery, Samsun, Turkey)
Bekir KURU, (Ondokuz Mayis University, Medical Faculty, General Surgery, Samsun, Turkey)
Kagan KARABULUT, (Ondokuz Mayis University, Medical Faculty, General Surgery, Samsun, Turkey)
Gokhan S. OZBALCI, (Ondokuz Mayis University, Medical Faculty, General Surgery, Samsun, Turkey)
Murat DEREBEY, (Ondokuz Mayis University, Medical Faculty, General Surgery, Samsun, Turkey)
Cafer POLAT, (Ondokuz Mayis University, Medical Faculty, General Surgery, Samsun, Turkey)
Aysegul ATMACA, (Ondokuz Mayis University, Medical Faculty, Endocrinology and Metabolic Diseases, Samsun, Turkey)
Kenan ERZURUMLU, (Ondokuz Mayis University, Medical Faculty, General Surgery, Samsun, Turkey)
Bulent KOCA (Bafra State Hospital, General Surgery, Samsun, Turkey)
Experimental Biomedical Research
3 0
Yıl: 2019 Cilt: 2 Sayı: 3 Sayfa Aralığı: 121 - 131 Metin Dili: İngilizce DOI: DOI: 10.30714/j-ebr.2019353197 İndeks Tarihi: 10-10-2020

Thyroid fine needle aspiration reporting rates and outcomes before and after Bethesda implementation: A single-center experience over 8 years

Öz:
Aimː To evaluate data from our hospital system before and after the implementation of the BethesdaSystem for Reporting Thyroid Cytology (TBSRTC) and comparison of our data with the previouslypublished studies.Methods: Seven hundred seventy-one patients with thyroid nodules who underwent fine needleaspiration biopsy (FNAB) and surgery at our institution were analyzed retrospectively. FNABresults were divided into two parts in terms of the period they related to: pre-TBSRTC (between 2005and 2010) and TBSRTC (between 2011 and 2013).Results: 341 FNAB were applied in the period of TBSRTC. Of the 341 FNAB, 53(16%) were nondiagnostic, 82(24%) were benign, 62(18%) were atypia of undetermined significance or follicularlesion of undetermined significance (AUS/FLUS), 28(8%) were follicular neoplasms and/orsuspicion of follicular neoplasms (FN/SFN), 95(28%) were suspicion for malignancy (SuspM), and21(6%) were malignant. Rates of malignancy reported on follow-up histopathological examinationwere non diagnostic in 11%, benign in 4.9%, AUS/FLUS in 23%, FN/SFN in 32%, SuspM in 44%,and malignant in 95.3%.Conclusions: In this study, the distribution of cases in TBSRTC categories and malignancy rates,differed from, recommended by TBSRTC and some studies. Implementation of TBSRTC didsignificantly affect our institution’s reporting rates.
Anahtar Kelime:

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık
  • [1]Burguera B, Gharib H. Thyroid incidentalomas. Prevalence, diagnosis, significance, and management. Endocrinol Metab Clin North Am. 2000;29(1):187-203.
  • [2]Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ, et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2009;19(11):1167-214.
  • [3]Gharib H, Papini E, Paschke R, Duick DS, Valcavi R, Hegedüs L, et al. AACE/AME/ETA Task Force on Thyroid Nodules. American Association of Clinical Endocrinologists, Associazione Medici Endocrinologi, and European Thyroid Association medical guidelines for clinical practice for the diagnosis and management of thyroid nodules: Executive Summary of recommendations. J Endocrinol Invest. 2010;33(5):287-91.
  • [4]Tandon S, Shahab R, Benton JI, Ghosh SK, Sheard J, Jones TM. Fine-needle aspiration cytology in a regional head and neck cancer center: comparison with a systematic review and meta-analysis. Head Neck. 2008;30(9):1246-52.
  • [5]Cibas ES, Ali SZ; NCI Thyroid FNA State of the Science Conference. The Bethesda System For Reporting Thyroid Cytopathology. Am J Clin Pathol. 2009;132(5):658-65.
  • [6]Ali SZ, Cibas ES. The Bethesda System for Reporting Thyroid Cytopathology. 2nd. New York: Springer; 2018.
  • [7]Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ, et al. Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2006;16(2):109-42.
  • [8]Meko JB, Norton JA. Large cystic/solid thyroid nodules: a potential false-negative fine-needle aspiration. Surgery. 1995;118(6):996–1003.
  • [9]Kuru B, Gulcelik NE, Gulcelik MA, Dincer H. The false-negative rate of fine-needle aspiration cytology for diagnosing thyroid carcinoma in thyroid nodules. Langenbecks Arch Surg. 2010; 395(2):127–32.
  • [10]Mondal SK, Sinha S, Basak B, Roy DN, Sinha SK. The Bethesda system for reporting thyroid fine needle aspirates: a cytologic study with histologic follow-up. J Cytol. 2013; 30(2): 94-99.
  • [11]Wu HH, Rose C, Elsheikh TM. The Bethesda system for reporting thyroid cytopathology: An experience of 1,382 cases in a community practice setting with the implication for risk of neoplasm and risk of malignancy. Diagn Cytopathol. 2012; 40(5):399-403.
  • [12]Harvey AM, Mody DR, Amrikachi M. Thyroid fine-needle aspiration reporting rates and outcomes before and after Bethesda implementation within a combined academic and community hospital system. Arch Pathol Lab Med. 2013;137(11):1664-68.
  • [13]Marchevsky AM, Walts AE, Bose S, Gupta R, Fan X, Frishberg D, et al. Evidencebased evaluation of the risks of malignancy predicted by thyroid fine-needle aspiration biopsies. Diagn Cytopathol. 2010;38(4):252-59.
  • [14]Broome JT, Solorzano CC. The impact of atypia/follicularlesion of undetermined significance on the rate of malignancy in thyroid fine-needle aspiration: evaluation of the Bethesda System for Reporting Thyroid Cytopathology. Surgery. 2011; 150(6):1234-41.
  • [15]Nayar R, Ivanovic M. The in determinate thyroid fine needle aspiration: experience from an academic center using terminology similar to that proposed in the 2007 National Cancer Institute Thyroid Fine Needle Aspiration State of the Science Conference. Cancer. 2009;117(3):195-202.
  • [16]Ozluk Y, Pehlivan E, Gulluoglu MG, Poyanli A, Salmaslioglu A, Colak N, et al. The use of the Bethesda terminology in thyroid fine-needle aspiration results in a lower rate of surgery for nonmalignant nodules: a report from a reference center in Turkey. Int J Surg Pathol. 2011;19(6):761- 71.
  • [17]Jo VY, Stelow EB, Dustin SM, Hanley KZ. Malignancy risk for fine-needle aspiration of thyroid lesions according to the Bethesda System for Reporting Thyroid Cytopathology. Am J Clin Pathol. 2010;134(3):450-56.
  • [18]Yassa L, Cibas ES, Benson CB, Frates MC, Doubilet PM, Gawande AA, et al. Long-term assessment of a multidisciplinary approach to thyroid nodüle diagnostic evaluation. Cancer. 2007;111(6):508-16.
  • [19]Yang J, Schnadig V, Logrono R, Wasserman PG. Fine-needle aspiration of thyroid nodules: a study of 4703 patients with histologic and clinical correlations. Cancer. 2007;111(5):306-15.
  • [20]Wang CC, Friedman L, Kennedy GC, Wang H, Kebebew E, Steward DL, Zeiger MA, et al. A large multicenter correlation study of thyroid nodüle cytopathology and histopathology. Thyroid. 2011;21(3):243- 51.
  • [21]Bongıovannı M, Spitale A, Faquin WC, Mazzucchelli L, Baloch ZW. The Bethesda System for Reporting Thyroid Cytopathology: A Meta-Analysis. Acta Cytol. 2012;56(4):333-39.
  • [22]Park JH, Yoon SO, Son EJ, Kim HM, Nahm JH, Hong S. Incidence and malignancy rates of diagnoses in the bethesda system for reporting thyroid aspiration cytology: an institutional experience. Korean J Pathol. 2014;48(2):133-39.
APA TARIM I, Kuru B, KARABULUT K, OZBALCI G, DEREBEY M, POLAT C, ATMACA A, ERZURUMLU K, KOCA B (2019). Thyroid fine needle aspiration reporting rates and outcomes before and after Bethesda implementation: A single-center experience over 8 years. , 121 - 131. DOI: 10.30714/j-ebr.2019353197
Chicago TARIM Ismail Alper,Kuru Bekir,KARABULUT Kagan,OZBALCI Gokhan S.,DEREBEY Murat,POLAT Cafer,ATMACA Aysegul,ERZURUMLU KENAN,KOCA Bulent Thyroid fine needle aspiration reporting rates and outcomes before and after Bethesda implementation: A single-center experience over 8 years. (2019): 121 - 131. DOI: 10.30714/j-ebr.2019353197
MLA TARIM Ismail Alper,Kuru Bekir,KARABULUT Kagan,OZBALCI Gokhan S.,DEREBEY Murat,POLAT Cafer,ATMACA Aysegul,ERZURUMLU KENAN,KOCA Bulent Thyroid fine needle aspiration reporting rates and outcomes before and after Bethesda implementation: A single-center experience over 8 years. , 2019, ss.121 - 131. DOI: 10.30714/j-ebr.2019353197
AMA TARIM I,Kuru B,KARABULUT K,OZBALCI G,DEREBEY M,POLAT C,ATMACA A,ERZURUMLU K,KOCA B Thyroid fine needle aspiration reporting rates and outcomes before and after Bethesda implementation: A single-center experience over 8 years. . 2019; 121 - 131. DOI: 10.30714/j-ebr.2019353197
Vancouver TARIM I,Kuru B,KARABULUT K,OZBALCI G,DEREBEY M,POLAT C,ATMACA A,ERZURUMLU K,KOCA B Thyroid fine needle aspiration reporting rates and outcomes before and after Bethesda implementation: A single-center experience over 8 years. . 2019; 121 - 131. DOI: 10.30714/j-ebr.2019353197
IEEE TARIM I,Kuru B,KARABULUT K,OZBALCI G,DEREBEY M,POLAT C,ATMACA A,ERZURUMLU K,KOCA B "Thyroid fine needle aspiration reporting rates and outcomes before and after Bethesda implementation: A single-center experience over 8 years." , ss.121 - 131, 2019. DOI: 10.30714/j-ebr.2019353197
ISNAD TARIM, Ismail Alper vd. "Thyroid fine needle aspiration reporting rates and outcomes before and after Bethesda implementation: A single-center experience over 8 years". (2019), 121-131. https://doi.org/DOI: 10.30714/j-ebr.2019353197
APA TARIM I, Kuru B, KARABULUT K, OZBALCI G, DEREBEY M, POLAT C, ATMACA A, ERZURUMLU K, KOCA B (2019). Thyroid fine needle aspiration reporting rates and outcomes before and after Bethesda implementation: A single-center experience over 8 years. Experimental Biomedical Research, 2(3), 121 - 131. DOI: 10.30714/j-ebr.2019353197
Chicago TARIM Ismail Alper,Kuru Bekir,KARABULUT Kagan,OZBALCI Gokhan S.,DEREBEY Murat,POLAT Cafer,ATMACA Aysegul,ERZURUMLU KENAN,KOCA Bulent Thyroid fine needle aspiration reporting rates and outcomes before and after Bethesda implementation: A single-center experience over 8 years. Experimental Biomedical Research 2, no.3 (2019): 121 - 131. DOI: 10.30714/j-ebr.2019353197
MLA TARIM Ismail Alper,Kuru Bekir,KARABULUT Kagan,OZBALCI Gokhan S.,DEREBEY Murat,POLAT Cafer,ATMACA Aysegul,ERZURUMLU KENAN,KOCA Bulent Thyroid fine needle aspiration reporting rates and outcomes before and after Bethesda implementation: A single-center experience over 8 years. Experimental Biomedical Research, vol.2, no.3, 2019, ss.121 - 131. DOI: 10.30714/j-ebr.2019353197
AMA TARIM I,Kuru B,KARABULUT K,OZBALCI G,DEREBEY M,POLAT C,ATMACA A,ERZURUMLU K,KOCA B Thyroid fine needle aspiration reporting rates and outcomes before and after Bethesda implementation: A single-center experience over 8 years. Experimental Biomedical Research. 2019; 2(3): 121 - 131. DOI: 10.30714/j-ebr.2019353197
Vancouver TARIM I,Kuru B,KARABULUT K,OZBALCI G,DEREBEY M,POLAT C,ATMACA A,ERZURUMLU K,KOCA B Thyroid fine needle aspiration reporting rates and outcomes before and after Bethesda implementation: A single-center experience over 8 years. Experimental Biomedical Research. 2019; 2(3): 121 - 131. DOI: 10.30714/j-ebr.2019353197
IEEE TARIM I,Kuru B,KARABULUT K,OZBALCI G,DEREBEY M,POLAT C,ATMACA A,ERZURUMLU K,KOCA B "Thyroid fine needle aspiration reporting rates and outcomes before and after Bethesda implementation: A single-center experience over 8 years." Experimental Biomedical Research, 2, ss.121 - 131, 2019. DOI: 10.30714/j-ebr.2019353197
ISNAD TARIM, Ismail Alper vd. "Thyroid fine needle aspiration reporting rates and outcomes before and after Bethesda implementation: A single-center experience over 8 years". Experimental Biomedical Research 2/3 (2019), 121-131. https://doi.org/DOI: 10.30714/j-ebr.2019353197
Sayfa Oluşturulma Tarihi
23-04-2024 13:45

İLETİŞİM

TÜBİTAK ULAKBİM TR Dizin

Yüzüncüyıl, İşçi Blokları Mahallesi

Muhsin Yazıcıoğlu Caddesi No:51/C

06530 Çankaya / ANKARA +90 (312) 298 92 00

trdizin@tubitak.gov.tr

TÜBİTAK ULAKBİM Ulusal Akademik Ağ ve Bilgi Merkezi Cahit Arf Bilgi Merkezi © Tüm Hakları Saklıdır. Gizlilik Politikası Kullanım Şartları